Related Experiment Video

Updated: Jun 25, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Use of high-throughput crystallography and in silico methods for structure-based drug design

Leslie W Tari1, Duncan E McRee, Andy J Jennings

  • 1ActiveSight, San Diego, California 92121, USA.

Methods of Biochemical Analysis
|February 25, 2009
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

High-Throughput Screening to Obtain Crystal Hits for Protein Crystallography
06:19

High-Throughput Screening to Obtain Crystal Hits for Protein Crystallography

Published on: March 10, 2023

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Jun 25, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

High-Throughput Screening to Obtain Crystal Hits for Protein Crystallography
06:19

High-Throughput Screening to Obtain Crystal Hits for Protein Crystallography

Published on: March 10, 2023

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Articles linked to this work by shared authors, journal, and citation graph.

Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenza.

Drug metabolism and disposition: the biological fate of chemicals·2026

Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice.

Nature microbiology·2025

Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression.

Nature communications·2019

A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).

Journal of medicinal chemistry·2014

Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

PloS one·2014

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.

Bioorganic & medicinal chemistry letters·2013

In silico and in vitro evaluation of new sulfonamide derivatives as VEGFR-2 inhibitors for cancer therapy.

Future medicinal chemistry·2026

Spectrophotometric determination of levofloxacin using bromophenol blue: insight into the structure of the formed supramolecular complex.

RSC advances·2026

Solacanin C, a new pregnane steroid from Solanum torvum fruits: structural elucidation, potent α-glucosidase inhibition, and in silico ADMET profiling.

RSC advances·2026

Iodine-mediated 2,5-di(aryl/heteroaryl)-1,3,4-oxadiazoles: synthesis, and in vitro and in silico studies of anticancer and antifungal properties.

RSC advances·2026

Identification of chemicals targeting dementia genes and pathways in the Comparative Toxicogenomics Database.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Metabolic profiling reveals subtype-specific responses to jerantinine A acetate in breast cancer cells.

The Analyst·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us